Japan’s Order-Made To Begin Testing First Product
This article was originally published in PharmAsia News
Order-Made Souyaku, a Japanese start-up biotech, plans to begin trials this spring in the United Kingdom for its first candidate, a drug to treat irritable-bowel syndrome. Order-Made's first drug, OMS210, is designed to bond with serotonin receptors to reduce overactivity of the bowel without the side effects associated with existing drugs. The start-up licensed the rights to the drug from R&R, a U.S. biotech venture, to develop it in China, the European Union, Japan, South Korea and the U.S. (Click here for more - a subscription may be required
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.